drugset / Trial / NCT02127697

Study of Efficacy and Safety of NVA237 in Patients With Poorly Controlled Asthma

NCT02127697

Phase 3 Withdrawn Novartis Pharmaceuticals
RandomizedParallel-groupDouble-blindTreatment

Summary

The study will assess efficacy, safety and tolerability of NVA237 compared to placebo in patients with poorly controlled asthma over 52 weeks of treatment.

Timeline

Start
2015-03
Primary completion
2017-05
Completion
2017-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Glycopyrrolate Small molecule Inhaled
Background Salbutamol Unknown

Indications